Q4 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Research analysts at William Blair boosted their Q4 2025 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a research report issued on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn $0.05 per share for the quarter, up from their prior forecast of $0.02. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.64) per share.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $18.00 to $22.00 in a research report on Tuesday, August 13th. Finally, Leerink Partners raised their price objective on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, ARS Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $24.00.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ:SPRY opened at $14.11 on Friday. The stock’s 50-day moving average price is $14.58 and its two-hundred day moving average price is $11.67. ARS Pharmaceuticals has a 12-month low of $4.27 and a 12-month high of $18.51.

Insider Activity

In related news, CEO Richard E. Lowenthal sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $12.93, for a total transaction of $1,293,000.00. Following the sale, the chief executive officer now directly owns 1,398,499 shares of the company’s stock, valued at approximately $18,082,592.07. This represents a 6.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction on Monday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider now directly owns 5,693 shares of the company’s stock, valued at approximately $79,702. This represents a 63.72 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,584,351 shares of company stock worth $24,152,378. 40.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in SPRY. Vanguard Group Inc. raised its stake in shares of ARS Pharmaceuticals by 37.0% during the first quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after purchasing an additional 779,969 shares in the last quarter. SG Americas Securities LLC grew its position in ARS Pharmaceuticals by 861.5% during the 2nd quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock worth $950,000 after purchasing an additional 99,986 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in ARS Pharmaceuticals during the third quarter valued at $2,584,000. Bank of New York Mellon Corp lifted its position in ARS Pharmaceuticals by 99.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,285 shares of the company’s stock worth $1,185,000 after buying an additional 69,394 shares in the last quarter. Finally, Raymond James & Associates bought a new stake in shares of ARS Pharmaceuticals in the 3rd quarter valued at approximately $2,969,000. 68.16% of the stock is currently owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.